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A 2-year-and-7-month-old boy underwent an emergent reconstruction surgery of the right ventricle-pulmonary
artery (RV-PA) conduit. Although he was successfully weaned from cardiopulmonary bypass (CPB) after reconstruction of
the RV-PA conduit, the bleeding continued despite the massive transfusion of red blood cell (RBC), fresh frozen plasma
(FFP), and platelets. Because of persistent bleeding and abnormal coagulation laboratory results, we administered the
recombinant activated factor VII (rFVIIa), which was not approved for use in the treatment of post-CPB coagulopathy.
After administration of rFVIIa, his coagulation data dramatically improved, the bleeding decreased, and the operation
was able to be finished.
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There have been increasing numbers of reports of “off-
label” use of the recombinant activated factor VII
(rFVIIa) to achieve hemostasis in various situations
including traumatic intractable bleeding [1, 2], cardiac
surgery [3, 4], and obstetrical massive bleeding [4].
However, there are few data regarding the appropri-
ate use of rFVIIa, especially in pediatric patients.
Here, we report a case of successful administration
of rFVIIa for refractory post-cardiopulmonary bypass
(CPB) bleeding in a child undergoing repeated car-
diac surgery.
Case presentation
A 2-year-and-7-month-old boy with 22q11.2 deletion
syndrome (height, 86 cm; body weight, 10 kg) was
scheduled for an emergent surgery to reconstruct the
right ventricle-pulmonary artery (RV-PA) conduit to
remove its compression on his right coronary artery,
causing the right ventricular failure. He was associated* Correspondence: mariko_i@muc.biglobe.ne.jp
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link to the Creative Commons license, and iwith tetralogy of Fallot, pulmonary atresia, major aorto-
pulmonary collateral arteries, and right aortic arch. He
underwent a systemic-pulmonary shunt (left subclavian
artery to central pulmonary artery) at 1 month of age
and right unifocalization and right Blalock-Taussig shunt
at 1 year and 3 months of age. When he was 2 years and
7 months old, he underwent RV-PA conduit and pul-
monary artery plasty. After the procedure, because of
the poor contraction of the right ventricle, weaning from
CPB failed and extracorporeal membrane oxygenation
(ECMO) was instituted, from which he was weaned on
postoperative day 11.
Twenty-two days after surgery, cardiac catheterization
revealed that his right coronary artery was com-
pressed by the RV-PA conduit, and the emergent re-
constitution of the RV-PA conduit was scheduled on
the same day.
Anesthesia was induced with 20 μg of fentanyl and
10 mg of rocuronium, and repositioning of the RV-PA
conduit was performed under CPB. He was successfully
weaned from CPB with the support of inhaled nitric
oxide (20 ppm), adrenaline (200 ng/kg/min), dopamine
(10 μg/kg/min), and dobutamine (10 μg/kg/min).
After reversal of heparin using protamine, persistentle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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pite continuous massive administration of red blood cell
(RBC), fresh frozen plasma (FFP), and platelets. At that
time, abnormal coagulation tests were noted with pro-
thrombin time (PT) of 36 % and international normalized
ratio of PT (PT-INR) of 1.73, activated partial thrombo-
plastin time (APTT) of 173 s, and fibrinogen was
172 mg/dl. The platelet count was 97,000/μL. As a rescue
treatment to reduce bleeding and to correct his coagula-
tion abnormality, a single dose of 100 μg/kg of rFVIIa
was intravenously administered. One hour later, coagula-
tion tests were almost normalized as shown in Table 1
and the hemorrhage decreased to 5–10 ml/kg/h, and the
operation was finished with the open sternum. He was
transferred to the Pediatric Intensive Care Unit
(PICU).
CPB time was 340 min, and his body temperature dur-
ing CPB was 32 °C. Operation time was 639 min, and
anesthesia time was 688 min. Total blood loss was
1480 ml, and required blood products were RBC 690,
FFP 725, and platelets 250 ml, respectively.
Five hours after the administration of rFVIIa, coagulation
data were comparable to the preoperative values (Table 1)
and the total bleeding dose was less than 1 ml/kg/h. No
additional rFVIIa was necessary. No thromboembolic
events were noted after its administration.
Fifty-two days after the second surgery, his sternum
and skin were able to be closed, and he was discharged
from PICU on day 157.
Discussion
We reported the use of rFVIIa in a child complicated
with persistent bleeding after cardiac surgery under
CPB. Because massive transfusion of FFP and platelets
failed to control post-CPB bleeding, we decided to use
rFVIIa though we knew that post-CPB coagulopathy
was not a licensed indication. In this case, rFVIIa was
administrated without previous parental informed con-
sent for its use. The administration of rFVIIa dramatic-
ally improved his coagulation data and reduced blood
loss.
Recombinant FVIIa is a hemostatic agent developed
for the treatment of hemophilia A or B with inhibitorsTable 1 Coagulation profile before and after administration of rFVIIa
Normal value Before surgery
Platelet /μl 130–400 × 103 438,000
PT % 80–120 53
PT-INR 0.9–1.1 1.37
APTT s 25–45 64
Fibrinogen mg/dl 180–360 308
rFVIIa recombinant activated coagulation factor VII, PT prothrombin time, PT-INR int(antibodies) to coagulation factor VIII or IX. Currently,
it is also approved to patients with congenital factor VII
deficiency or the patients who have acquired antibodies
to factor VIII, which is called as acquired hemophilia A.
Furthermore, there have been increasing numbers of
reports describing the off-label use of rFVIIa, which was
effective in controlling refractory bleeding in nonhemo-
philic patients [1–4].
Recombinant FVIIa is considered to work by two
mechanisms (Fig. 1): tissue factor (TF)-dependent and
independent mechanisms. In the TF-dependent mech-
anism, FVIIa/TF complexes activate coagulation fac-
tors IX and X and activated factor X combines with
factor V, resulting in an increase of thrombin gener-
ation. In the TF-independent mechanism, FVIIa can
directly activate factor X on the platelet surface with-
out the presence of TF. These mechanisms activate
and aggregate platelets, resulting in formation of stabi-
lized clots [5].
Uncontrolled bleeding after CPB is a critical problem
especially in young children undergoing complex cardiac
repair. The proposed mechanisms of the post-CPB coag-
ulopathy in these young patients include (1) large circuit
priming volume compared to the circulating blood
volume, leading to dilution of platelets and coagulation
factors; (2) long, complex cardiac repairs with extensive
suture lines; (3) effects of hypothermia on both plasma
coagulation factors and platelet function; (4) consump-
tion of coagulation factors due to tissue injury, contact
activation, and transfusion of suctioned pericardial
blood; and (5) residual heparin or other anticoagulants
[3, 5]. Adding to the repeated procedures, our patient
was on the ECMO until 11 days before and underwent
cardiac catheterization a few hours before the surgery
in the unstable hemodynamic and debilitating state.
These conditions might have further influenced the
coagulation derangement, as partly shown by the ab-
normal data of PT, PT-INR, and APTT before surgery
(Table 1).
There is no consensus on how to manage post-
CPB coagulopathy in pediatric patients. The transfu-
sion of platelets is the initial treatment for ongoing
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Fig. 1 Mechanism of action of rFVIIa
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platelet administration, institutions vary in their transfu-
sion approach.
The congenital Cardiac Anesthesia Society (CCAS)
Task Force recommends that rFVIIa can be considered
for the management of post-CPB bleeding refractory to
maximal standard hemostatic therapy in pediatric car-
diac surgery [3]. This criterion for use of rFVIIa could
be applied to our case.
It is not clear how the administration of rFVIIa
worked dramatically in reducing bleeding in this case.
The high dose of FVIIa might have stimulated the co-
agulation cascade by the activation of factors IX and X
in combination with factors VIII and V through TF-
dependent mechanism. Or the high dose of FVIIa might
have stimulated the coagulation cascade, leading to sub-
sequent thrombin generation through TF-independent
mechanism. The latter mechanism seems more plausible
because this pathway is enabled only when the high dose
of FVIIa is provided and does not require the presence
of factors V, VIII, and IX.
To exclude the possibility of acquired hemophilia A,
the measurement of antibodies to coagulation factor VIII
is required, which we did not perform in this case.
Concerning the dosage of rFVIIa, Pychyńska-Pokorska
et al. reported that the effective dose in cardiac surgery
was 131.7 ± 69.8 μg/kg in neonates, 104.6 ± 36.0 μg/kg in
infants, and 44.6 ± 15.3 μg/kg in children older than
1 year of age [7]. A systematic literature review showed
that the effective dose was 93.2 μg/kg, the frequency ofadministration was 2, and the most common adminis-
tration interval was 2 h [3]. Since neonates and infants
have immature coagulation system than adults [3], and
the plasma clearance of rFVIIa is significantly higher
in children than in adults (67 ml/kg/h in children,
36.6 ml/kg/h in adults) [3], children might require lar-
ger dose of rFVIIa than adults to achieve appropriate
hemostasis. Considering the age and body weight of
our patient, our dose of 100 μg/kg is comparable with
the recommended dose.
One of the complications of administering rFVIIa
is a thromboembolic event [8], especially in the pa-
tients with ECMO [3]. It is stated that we should
properly assess the risk-benefit of administration
rFVIIa under ECMO [9]. A thromboembolic event
was not noted in our patient.Conclusions
We experienced a case of a successful “off-label” use of
rFVIIa in a pediatric cardiac surgery. In the case of
massive post-CPB bleeding refractory to standard
hemostatic therapy, the administration of rFVIIa may be
taken into consideration. To accumulate the successful
cases is important to define the criteria of uses of rFVIIa
in the future.Consent
Written informed consent was obtained from the parent
of the patient for publication of this case report. A copy
Ishihara et al. JA Clinical Reports  (2015) 1:9 Page 4 of 4of the written consent is available for review by the
Editor of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MI: data collection, literature search, manuscript drafting and anesthesiologist
involved in the case. YM: manuscript drafting and anesthesiologist involved
in the case. AT: manuscript drafting. KK: manuscript drafting and supervision.
All authors read and approved the final manuscript.
Author details
1Department of Anesthesiology, Shiga University of Medical Science, Seta
Tsukinowa-cho, Otsu, Shiga, Japan. 2Department of Anesthesiology, Osaka
Medical Center and Research Institute for Maternal and Child Health, 840
Murodocho, Izumi, Osaka, Japan.
Received: 27 May 2015 Accepted: 4 August 2015
References
1. Yao D, Li Y, Wang J, Yu W, Li N, Li J. Effects of recombinant activated factor
VIIa on abdominal trauma patients. Blood Coagul Fibrinolysis. 2014;25:33–8.
2. Brown CV, Sowery L, Curry E, Valadka AB, Glover CS, Grabarkewitz K, et al.
Recombinant factor VIIa to correct coagulopathy in patients with traumatic
brain injury presenting to outlying facilities before transfer to the regional
trauma center. Am Surg. 2012;78:57–60.
3. Guzzetta NA, Russell IA, Williams GD. Review of the off-label use of
recombinant activated factor VII in pediatric cardiac surgery patients.
Anesth Analg. 2012;115:364–78.
4. Zatta A, Mcquilten Z, Kandane-Rathnayake R, Isbister J, Dunkley S, Mcneil J,
et al. The Australian and New Zealand Haemostasis Registry: ten years of
data on off-licence use of recombinant activated factor VII. Blood Transfus.
2015;13:86–99.
5. Barua A, Rao VP, Ramesh B, Barua B, El-Shafei H. Salvage use of activated
recombinant factor VII in the management of refractory bleeding following
cardiac surgery. J Blood Med. 2011;2:131–4.
6. Hornykewycz S, Odegard KC, Castro RA, Zurakowski D, Pigula F, DiNardo JA.
Hemostatic consequences of a non-fresh or reconstituted whole blood
small volume cardiopulmonary bypass prime in neonates and infants.
Paediatr Anaesth. 2009;19:854–61.
7. Pychyńska-Pokorska M, Pągowska-Klimek I, Krajewski W, Moll JJ. Use of
recombinant activated factor VII for controlling refractory postoperative
bleeding in children undergoing cardiac surgery with cardiopulmonary
bypass. J Cardiothorac Vasc Anesth. 2011;25:987–94.
8. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated
factor VII in randomized clinical trials. N Engl J Med. 2010;363:1791–800.
9. Dominguez TE, Brown KL. Activated recombinant factor VII and
extracorporeal membrane oxygenation: everything is all right, nothing is
wrong? Pediatr Crit Care Med. 2010;11:155–6.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
